Quest Diagnostics Incorporated (DGX) has had a highly successful period, with its stock reaching a
52-week high of $152.88. Several acquisitions have bolstered its foothold in the diagnostic services space, including its outreach in laboratory services business from universities and hospitals, increasing its profits and considerably expanding its reach in the market. Recent
earnings reports show positive results, indicating strong financial performance and promising future prospects. DGX has also made inroads in the fields of AI and digital pathology, deploying technologies that
accelerate cancer diagnosis. Recent ventures include the launch of a
Micronutrient Deficiency Panels and a
MelaNodal Predict™ Test that personalize melanoma risk prediction. Also noteworthy is DGX's resilient commitment to societal values, having been named a '
Best Place to Work for Disability Inclusion' for seven consecutive years. Additionally, the company has expanded into Canada via a nearly $1 billion acquisition of LifeLabs. Despite competition and the challenges of the market, the company maintains a positive
outlook for 2024, fortified by the release of $1.85 billion of Senior Notes.
Quest Diagnostics DGX News Analytics from Tue, 24 Oct 2023 07:00:00 GMT to Sun, 25 Aug 2024 02:37:25 GMT -
Innovation 9
- Information 8
- Rumor 7
